Paul Thomen

Friday, 15 February 2013

Competitive Intelligence Hologic and Toshiba in the Global Diagnostic Imaging Sector

This strategic assessment of Hologic and Toshiba, one of the world’s leading diagnostic imaging companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and RD programs. The new report from Venture Planning Group presents a comprehensive analysis of the company’s performance, capabilities, goals, and strategies in the global diagnostic imaging market

Inquire For Discount of Hologic Diagnostic Imaging Sector @

Inquire For Discount of Toshiba Diagnostic Imaging Sector @

Table of Content

Section I: Executive Summary
A 3-15 Page Synopsis Of Key Sections.
Section II: Business Organization
History Of The Company’s Diagnostic Imaging Business Evolution, Which Is Important To Understanding The Corporate Culture, Management Mentality And Strategies.
Recent Acquisitions, Divestitures And Major Organizational Changes.
Current Organizational Structure.
Section III: Senior Management
Names, Titles And Background Of Key Executives.
Section IV: Facilities And Employees
Administrative, Manufacturing And R&D Facilities In The U.S. And Abroad.
Manufacturing Practices.
New Plants Under Construction.
The U.S. And International Work Force Size And Distribution.
Section V: Technological Know-How
Internally Developed And Acquired Diagnostic Imaging And Related Technologies, Including X-Ray, Ultrasound, Mri, Ct, Nuclear Medicine, Pet, Pacs, And Others.
Section VI: Product Portfolio
Placements And Installed Base Of Major Systems In The U.S. And Abroad, By Modality.
Review Of Major Product Lines.
Applications, Advantages And Weaknesses Of Leading Products.
Section VII: Marketing Tactics
Promotional Tactics.
Distribution Approaches.
Product Service And Support.
Customer Relations.
Section VIII: Financial Analysis
Estimated Sales And Operating Profit By Division, Geographic Region And Product Line.
Five-Year Sales And Operating Profit Performance.
Section IX: R&D Expenditures And Major Programs
Estimated R&D Budget.
Research Facilities And Staff.
New Technologies, Systems And Applications In Development.
Section X: Collaborative Arrangements
Joint Ventures, Distribution, O.E.M. And Licensing Partners, Both Industrial And Academic.
Terms Of Collaborative Agreements And Specific Products Involved.
Section XI: Strategic Direction
Specific Business, New Product Development And Marketing Strategies.
Anticipated Acquisitions, Joint Ventures And Divestitures.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.